P/E ratio for InnovAge (INNV)
P/E ratio as of September 2023 (TTM): -21.1
According to InnovAge's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -21.0645. At the end of 2021 the company had a P/E ratio of 167.
P/E ratio history for InnovAge from 2021 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 167 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Merck MRK | 86.0 | -508.50% | 🇺🇸 USA |
 Cocrystal Pharma
COCP | -0.8734 | -95.85% | 🇺🇸 USA |
 AcelRx Pharmaceuticals
ACRX | -0.1945 | -99.08% | 🇺🇸 USA |
 Horizon Therapeutics
HZNP | 60.2 | -385.98% | 🇮🇪 Ireland |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.